State Street
IKT icon

State Street’s Inhibikase Therapeutics IKT Stock Holding History

State Street’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.83M Buy
1,685,816
+1,130,967
+204% +$2.01M ﹤0.01% 3193
2025
Q4 		$1.14M Buy
554,849
+47,100
+9% +$75K ﹤0.01% 3500
2025
Q3 		$823K Buy
507,749
+109,937
+28% +$190K ﹤0.01% 3552
2025
Q2 		$776K Buy
397,812
+355,928
+850% +$697K ﹤0.01% 3538
2025
Q1 		$91.7K Hold
41,884
– – ﹤0.01% 3988
2024
Q4 		$136K Buy
41,884
+31,800
+315% +$79.3K ﹤0.01% 3930
2024
Q3 		$13.1K Hold
10,084
– – ﹤0.01% 4251
2024
Q2 		$13.2K Hold
10,084
– – ﹤0.01% 4310
2024
Q1 		$21.8K Hold
10,084
– – ﹤0.01% 4285
2023
Q4 		$12.8K Hold
10,084
– – ﹤0.01% 4381
2023
Q3 		$14.2K Buy
10,084
+2
+0% +$4 ﹤0.01% 4476
2023
Q2 		$35.1K Sell
10,082
-1
-0% -$4 ﹤0.01% 4505
2023
Q1 		$39.8K Hold
10,083
– – ﹤0.01% 4556
2022
Q4 		$30.3K Hold
10,083
– – ﹤0.01% 4667
2022
Q3 		$55K Hold
10,083
– – ﹤0.01% 4633
2022
Q2 		$45K Buy
10,083
+400
+4% +$2.36K ﹤0.01% 4741
2022
Q1 		$86K Buy
9,683
+200
+2% +$1.61K ﹤0.01% 4685
2021
Q4 		$84K Buy
+9,483
New +$105K ﹤0.01% 4612

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street's IKT Position: Q1 2026 in Review

State Street increased its Inhibikase Therapeutics (IKT) stake by 204% in Q1 2026, buying an estimated $2.01M and bringing the position to 1,685,816 shares worth $2.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3193.

State Street first reported a position in IKT in Q4 2021 and has held it in 18 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • State Street held 1,685,816 shares of Inhibikase Therapeutics worth $2.83M as of Q1 2026.
  • State Street bought 1,130,967 Inhibikase Therapeutics shares in Q1 2026, an estimated $2.01M.
  • Inhibikase Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3193 holding.
  • State Street first reported a position in Inhibikase Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.